It is worthwhile to mention that NSCLC next-generation sequencing (NGS) studies demonstrated that the NRF2 pathway is aberrant in a significant fraction of NSCLCs, either by activating mutations in NRF2 or by inactivating mutations or deletions in NRF2 inhibitor and tumor suppressor Kelch-like ECH-associated protein 1 (KEAP1)39, 40. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.